FDA Obesity Drug Guidance Should Relax Trial Enrollment Criteria, PhRMA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Patients with a body mass index exceeding 25, rather than BMI>27, should be allowed in trials, PhRMA says. Revised guidance should also eliminate the need for a weight-loss attempt immediately before enrollment, the association suggests.